Editors’ Note: This is the second in a new series of interviews with investigators who have made groundbreaking contributions to understanding bone health and disease. See the first interview, with T. John Martin, here http://www.nature.com/ bonekey/knowledgeenvironment/2013/130424/bonekey201373/ full/bonekey201373.html. Stavros C. Manolagas, MD, PhD, is The Thomas E. Andreoli, MD, MACP Clinical Scholar Chair in Internal Medicine at the University of Arkansas for Medical Sciences (UAMS) in Little Rock, Arkansas, USA. He is also a Distinguished Professor of Medicine; Director, Division of Endocrinology and Metabolism; Director, the UAMS/VA Center for Osteoporosis and Metabolic Bone Diseases; and Vice Chair for Research, in the Department of Internal Medicine at UAMS. He is also Chief, Endocrinology Section at Central Arkansas Veterans Healthcare System. Professor Manolagas has spent a distinguished career studying the effects of steroid hormones on bone, making seminal contributions to understanding the cellular and molecular mechanisms by which estrogens, androgens and glucocorticoids influence the skeleton. In particular, his work has driven a paradigm shift toward thinking about osteoporosis as a disease of aging, rather than solely as a condition of estrogen deficiency. Professor Manolagas spoke recently with Neil Andrews, BoneKEy Features Editor, to discuss the genesis of his interest in steroid hormone action on bone, what drove his thinking away from an estrogen-centric view of osteoporosis and toward an age-related perspective on the disease, and what research questions he is pursuing now. An edited version of their conversation appears below. BoneKEy: How did you become interested in studying the effects of steroid hormones on bone? Stavros Manolagas: After my clinical training at the University of Athens, I was given an opportunity to do PhD work at the University of Manchester in England. My mentor then, David Anderson, had just returned from the United States, where he had learned methods for measuring multiple adrenal steroids simultaneously. David was collaborating with Robert Lindsay, who at the time was a Senior Registrar at The Royal Infirmary in Glasgow, Scotland. Robert had just reported, in studies using photon absorptiometry to measure bone density, that women who had their ovaries removed could be divided into two groups: those who lost bone quickly and those who lost bone slowly. The clinical part of my PhD thesis tested the hypothesis that adrenal steroids contributed to the variation in bone loss that follows loss of estrogens. We published that research from my PhD work in Lancet. For the basic research part of my thesis that would complement the clinical component, the plan was that I would study receptors for glucocorticosteroids and estrogens in bone. Citation: IBMS BoneKEy 10, Article number: 405 (2013) | doi:10.1038/bonekey.2013.139 & 2013 International Bone & Mineral Society All rights reserved 1940-8692/13 www.nature.com/bonekey
Read full abstract